Valtech Cardio
Mitral Valve Repair Implants
Company Overview
Snapshot
Founded in January 2005 by Amir Gross, Valtech Cardio operated with 1–10 employees. The company raised $19.67 million across two funding rounds from three investors. In January 2017, Valtech Cardio was acquired by Edwards Lifesciences.
Business overview
Valtech Cardio is a medical device company specializing in the development of innovative solutions for mitral valve repair and replacement. Its core products include the Cardinal system, designed to facilitate annuloplasty ring implantation, and the V-Chordal system, an artificial chordae system for echo-guided chord length modification. The company serves the healthcare industry, specifically targeting hospitals, surgeons, and doctors with its cardiology and minimally-invasive surgical devices.
Strategic signal
This event signals a successful exit for early investors and validates the company's innovative approach to addressing critical cardiovascular needs, integrating its solutions into a larger global healthcare portfolio.
Log in to access full profile ›Company Intelligence Q&A
- What is Valtech Cardio's primary focus?
- Valtech Cardio specializes in developing devices for mitral valve repair and replacement, offering solutions like the Cardinal for annuloplasty ring implantation and the V-Chordal system for artificial chordae.
- When was Valtech Cardio acquired?
- Valtech Cardio was acquired by Edwards Lifesciences in January 2017.
- Which company previously attempted to acquire Valtech Cardio?
- HeartWare previously announced an acquisition of Valtech Cardio for $860 million in September 2015, but this acquisition was later canceled in January 2016.
- What was the total capital raised by Valtech Cardio?
- Valtech Cardio raised a total of $19.67 million across two funding rounds.